Effect of platinum ‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer.

Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer. Oncol Rep. 2019 Jun 03;: Authors: Okita R, Maeda A, Shimizu K, Nojima Y, Saisho S, Nakata M Abstract Platinum‑based chemotherapy improves the clinical outcome of patients with non‑small cell lung cancer (NSCLC), although tumors often become refractory after treatment. Immunohistochemical staining was performed to investigate the expression levels of natural killer group 2 member D (NKG2D) ligands, programmed cell death‑1 ligand 1 (PD‑L1), and human leucocyte antigen (HLA)‑class I in tissue samples collected from 10 NSCLC patients who received platinum‑based chemotherapy followed by surgery. Additionally, the effects of repeated exposure to cisplatin on the expression of NKG2D ligands, PD‑L1 and HLA‑class I in NSCLC cell lines were assessed by flow cytometry. We found upregulation of PD‑L1 or downregulation of NKG2D ligands in 5 of the 10 NSCLC cases, leading to the attenuation of NK cell‑mediated tumor cell death. Moreover, upregulation of PD‑L1 or downregulation of HLA‑class I were observed in 6 cases, supporting tumor escape from T cell immunity. An in vitro assay showed that repeated exposure to cisplatin enhanced the expression of PD‑L1 and NKG2D ligands in NSCLC cell lines. Notably, interferon gamma (IFNγ) stimuli en...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Related Links:

ConclusionVinorelbine pharmacokinetics were found to be comparable between Asian and European patients. No relevant influence of ethnicity on vinorelbine bioavailability and clearance for oral and intravenous routes of administration was observed.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
ConclusionsOur study revealed the clinical characteristics and prognoses of patients who became ineligible for the PACIFIC trial after CRT. Physicians should be careful while prescribing CRT for patients with characteristics such as old age, male gender, and radiation therapy with V20  ≥ 35%.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
ConclusionNab-paclitaxel may be a safe and effective later-line chemotherapeutic option for previously treated advanced NSCLC after standard of chemotherapies based on other trials.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Lung cancer is the leading cause of cancer death worldwide, and non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers [1]. For advanced disease (stage IIIB-IV), first-line treatment options have evolved in recent years; however, the mainstay consists of platinum-based chemotherapy doublets [2,3].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Lung cancer remains a significant health care burden, accounting for 11.6% (2.094 million) of all cancer cases and 18.4% (1.8 million) of cancer related deaths [1]. With advances in targeted therapeutics and immunotherapy agents [2], five-year survival rates are improving with recent SEER data indicating a rate of 19.4% [3]. However, chemotherapy is still widely used, with more recent trials combining traditional chemotherapy with newer agents [4]. Cisplatin, cis-Diamineplatinum (II) dichloride, is a common chemotherapeutic agent used in the treatment of advanced NSCLC [5 –9], and is currently one of the most effecti...
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
AbstractPurposeTo evaluate alterations in pulmonary function indices after helical tomotherapy and explore potential associations with biologically corrected dosimetric parameters.Patients and methodsIn 64  patients with inoperable locally advanced non-small cell lung cancer, pulmonary function tests before and within 6 months after radiotherapy were evaluated retrospectively. In the case of concurrent chemotherapy a total dose of 67.2 Gy was delivered, otherwise 70.5 Gy was provided. In 44 pa tients, late pulmonary function changes (≥6 months after radiotherapy) could also be assessed.Resul...
Source: Strahlentherapie und Onkologie - Category: Cancer & Oncology Source Type: research
Conclusions: Both HITHOC and TALC are equally effective and safe therapeutic options in treating patients with MPE and NSCLC with acceptable survival. The study revealed independent clinical risk factors influencing survival, which could be utilized as starting points for larger clinical studies. Keywords: Pleurodesis; pleural effusion; malignant; carcinoma; non-small cell lung; hyperthermia. PMID: 31285871 [PubMed]
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
Authors: Sandler JE, D'Aiello A, Halmos B Abstract The management of advanced non-small cell lung cancer (NSCLC) has been revolutionized in recent years with the introduction of biomarker-targeted molecular therapies and immune checkpoint inhibitors. In contrast, since adjuvant chemotherapy was first established twenty years ago as the standard of care, little has changed for resected early-stage (IB-IIIA) patients for whom the potential for cure is greatest. In this manuscript we will review recently presented data as well as ongoing/planned studies in this arena. So far, investigative efforts have yielded mixed r...
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
Immune checkpoint inhibitors (ICIs) in combination with chemotherapy significantly improve the disease control and reduce the risk of disease progression but have no statistically significant survival benefits compared with ICIs alone in the first ‐line treatment of PD‐L1 high expression (TPS ≥ 50%) advanced NSCLC. The findings support the rationale for using pembrolizumab alone in the treatment of advanced NSCLC with PD‐L1 ≥ 50%. However, a significant survival benefit compared with chemotherapy alone even in PD‐L1 low or neg ative expression advanced NSCLC was observed in combination the...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Study